Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...
In December 2025, Castle Biosciences reported Nature Communications data from the largest prospective, multicenter uveal melanoma study showing that combining its DecisionDx-UM test with PRAME gene ...
New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...
DecisionDx-Melanoma demonstrates robust clinical utility and validated performance, supported by high-quality (SORT A) evidence showing accurate and consistent prognostic information for patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback